Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Patients with severe AS should be evaluated by a multidisciplinary Heart Valve Team when intervention is considered. It is important to have a pathway to schedule the appropriate patient for this procedure.
Heart valve team
Patients with severe AS should be evaluated by a multidisciplinary Heart Valve Team when intervention is considered.
Team members include:
- Cardiology Valve Expert
- Cardiovascular Imaging Expert(s)
- Interventional Cardiologist
- Cardio-Thoracic Surgeon
- Cardiovascular Anesthesiologist
- Valve Clinic Care Coordinators
Their specific tasks are:
- Review the patient’s medical condition and the severity of the valve abnormality
- Determine which interventions are indicated, technically feasible, and reasonable
- Discuss benefits and risks of these interventions with the patient and family, keeping in mind their values and preferences.
Critical pathway
Abbreviations:
CV: Cardiovascular, AVR: aortic valve replacement, AS: aortic stenosis, MR: Mitral regurgitation, AR: Aortic regurgitation, PAP: Pulmonary artery pressure, RV: right ventricle, CTA: CT angiography, PA: Pulmonary artery, TEE: Trans Esophageal Echocardiography, TTE: Trans Thoracic Echocardiography
Care Providing Team
| | Primary Care Provider | |
| | | | | | |
| | Clinical Cardiologist | |
| | | | | | |
| | Heart Valve Team:
- Cardiology Valve Expert
- CV Imaging Expert(s)
- Interventional Cardiologist
- CT Surgeon
- CV Anesthesiologist
- Valve Clinic Care Coordinators
| |
| | | | | | |
| | Hands off back to the Primary Care Provider and Clinical Cardiologist | |
|
Clinical Evaluation
| | AS Symptoms or Signs | |
| | | | | | |
| | Severe AS with Indication for AVR | |
| | | | | | |
| | Potential TAVR Candidate | |
| | | | | | |
| | Patient Selection & Evaluation
- Shared Decision Making
- ❑ Goals of Care Clinical Information
- • Major CV comorbidites
- • Major non-CV comorbidities
- • Risk score assessment
- ❑ Functional Assessment
- • Frailty
- • Physical and cognitive function
- ❑ Risk Categories
- • Low risk
- • Intermediate risk
- • High or extreme risk
| |
| | | | | | |
| | TAVR Procedure
- ❑ Preplanning
- • Valve choice and access options
- • Anesthesia and procedure location
- • Anticipated complication management
- ❑ Procedural Details
- • Vascular access and closure
- • Valve delivery and deployment
- • Postdoploymont evaluation
- • Management of complications
| |
| | | | | | |
| | Post TAVR Management
- ❑ Early Post TAVR
- • Postprocedure monitoring and pain management
- • Early mobilization and discharge planning
- • Monitor for conduction abnormalities
- ❑ Long term Management
- • Antithrombotic therapy and endocarditis prophylaxis
- • Management of concurrent cardiac disease
- • Post-TAVR complications
| |
|
Cardio-vascular Imaging
| | Pre TAVR
- ❑ Echo
- • Aortic valve anatomy
- • Confirm AS severity
- • LV function
- • MR. AR. PAP. RV function
- ❑ TAVR protocol CTA
- • Vascular access
- • Annular sizing
- • Aortic root anatomy
- • Interventional planning
| |
| | | | | | |
| | Echo
- ❑ (TEE or TTE)
- • Annular sizing
- • Valve placement
- • Paravalvular leak
- • Procedural complications
| |
| | | | | | |
| | Post TAVR Imaging
- ❑ Echo and ECG post-procedure, at 30 days and then annually
- • Valve function
- • LV size and function
- • PA systolic pressure
- • Cardiac rhythm
| |
|
References